Literature DB >> 12730752

Phalangeal quantitative ultrasound technology and dual energy X-ray densitometry in patients with primary hyperparathyroidism: influence of sex and menopausal status.

V Camozzi1, F Lumachi, F Mantero, M Piccolo, G Luisetto.   

Abstract

Fifty-one patients with surgically proven primary hyperparathyroidism (PHPT), 11 males and 40 females, mean age+/-SD: 55.9+/-14.1 years, and 58 age- and sex-matched normal subjects were studied. The femoral and L(2)-L(4) bone mineral density (BMD; Hologic QDR 4500 C), as well as quantitative ultrasonometry (QUS; DBM-Sonic 1200) of the phalanges of both hands were measured in patients and controls. QUS measurements included amplitude-dependent speed of sound (AD-SoS), and other parameters derived from the graphic trace: signal dynamics (Sdy), first wave amplitude (FWA), bone transmission time (BTT) and ultrasound bone profile index (UBPI). Patients with PHPT showed significantly lower dual energy X-ray densitometry (DXA) values and QUS parameters compared to controls (lumbar spine Z-score: controls: -0.16+/-1.12, PHPT: -0.70+/-1.14, P=0.016; femoral neck Z-score: controls: -0.28+/-1.74, PHPT: -1+/-1.01, P=0.013; total femur Z-score: controls: -0.33+/-1.12, PHPT: -1.01+/-0.95, P=0.0013; AD-SoS Z-score: controls: -0.89+/-1.22, PHPT: -1.97+/-1.78, P=0.0003; FWA Z-score: controls: 0.36+/-1, PHPT: 0.62+/-0.85, P<0.0001; BTT Z-score: controls: 0.04+/-1.03, PHPT: -0.45+/-1.37, P=0.044; UBPI Z-score: controls: -0.02+/-1.01, PHPT: -0.68+/-1.05, P=0.002; SDy (mV/micros(2)): controls: -295+/-256, PHPT: -498+/-306, P=0.0003). In male patients, BMD values measured on the lumbar spine and femoral regions were similar to those found in male controls, while QUS values were significantly lower (lumbar spine Z-score: controls: -1.05+/-1.41, PHPT: -1.75+/-1.21, P=0.21; femoral neck Z-score: controls: -0.37+/-1.84, PHPT: -1.11+/-1.14, P=0.27; total femur Z-score: controls: -0.16+/-1.59, PHPT: -1.02+/-1.20, P=0.168; AD-SoS Z-score: controls: -0.52+/-1.58, PHPT: -1.57+/-1.77, P=0.149; FWA Z-score: controls: 0.67+/-1.01, PHPT: -0.74+/-0.79, P=0.0016; BTT Z-score: controls: 1.22+/-0.83, PHPT: 0.75+/-1.51, P=0.478; UBPI Z-score: controls: 0.56+/-0.94, PHPT: -0.47+/-1.10, P=0.025; SDy (mV/micros(2)): controls: -167+/-230, PHPT: -485+/-307, P=0.01). Women with PHPT were further divided into two subgroups: premenopause ( n=11) and postmenopause ( n=29). The premenopausal women with PHPT showed significantly lower DXA values than those of the premenopausal control ones, but similar QUS parameters (lumbar spine Z-score: controls: 0.12+/-0.66, PHPT: -0.59+/-0.85, P=0.03; femoral neck Z-score: controls: 0.06+/-2.85, PHPT: -1.48+/-1.05, P=0.11; total femur Z-score: controls: -0.51+/-0.97, PHPT: -1.48+/-0.63, P=0.009; AD-SoS Z-score: controls: 0.78+/-0.89, PHPT: -1.26+/-1.88, P=0.42; FWA Z-score: controls: 1.14+/-0.77, PHPT: 0.12+/-0.80, P=0.007; BTT Z-score: controls: 0.13+/-0.60, PHPT: 0.25+/-1.15, P=0.757; UBPI Z-score: controls: 0.73+/-0.49, PHPT: 0.24+/-0.96, P=0.15; SDy (mV/micros(2)): controls: -118+/-123, PHPT: -271+/-301, P=0.106). The postmenopausal women with PHPT showed both DXA and QUS parameters significantly lower than those found in the postmenopausal controls (lumbar spine Z-score: controls: 0.09+/-0.96, PHPT: -0.31+/-0.96, P=0.004; femoral neck Z-score: controls: -0.38+/-1.01, PHPT: -0.76+/-0.91, P=0.14; total femur Z-score: controls: -0.33+/-0.97, PHPT: -0.81+/-0.92, P=0.057; AD-SoS Z-score: controls: -1.08+/-1.17, PHPT: -2.38+/-1.68, P=0.31; FWA Z-score: controls: -0.013+/-0.81, PHPT: -0.86+/-0.74, P=0.0009; BTT Z-score: controls: -0.58+/-0.68, PHPT: -1.13+/-0.93, P=0.016; UBPI Z-score: controls: -0.62+/-0.83, PHPT: -1.11+/-0.82, P=0.034; SDy (mV/micros(2)): controls: -419+/-242, PHPT: -589+/-269, P=0.012). The relative risk of osteopenia was significantly increased in PHPT patients at several measurement sites. There was a highly significant correlation between spine and femoral BMD and QUS parameters, while PTH serum levels did not correlate with any of the densitometric variables. In conclusion, QUS parameters would seem to be able to distinguish patients with PHPT from normal controls in male subjects and in postmenopausal women, but not in premenopausal women. This would suggest that the higher estrogen levels in premenopausal patients might preserve the bone from significant structural changes. This may also suggest that hyperparathyroidism, in addition to the reduction of bone mineral content, can cause an alteration of bone structure with an additional increase in fracture risk in postmenopausal women. Furthermore, the alterations in QUS parameters in patients who do not show significant changes in DXA measurements suggest an involvement of bone that is independent of mineral content and may be helpful for selecting candidates for surgery, according to NIH criteria.

Entities:  

Mesh:

Year:  2003        PMID: 12730752     DOI: 10.1007/s00198-003-1407-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  36 in total

Review 1.  HRT in the prevention and treatment of osteoporosis.

Authors:  P D Delmas
Journal:  J Epidemiol Biostat       Date:  1999

Review 2.  Primary hyperparathyroidism: pathophysiology and impact on bone.

Authors:  A Khan; J Bilezikian
Journal:  CMAJ       Date:  2000-07-25       Impact factor: 8.262

3.  The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats.

Authors:  H Dobnig; R T Turner
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

Review 4.  The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.

Authors:  P Christiansen
Journal:  APMIS Suppl       Date:  2001

5.  Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.

Authors:  B J Orr-Walker; M C Evans; J M Clearwater; A Horne; A B Grey; I R Reid
Journal:  Arch Intern Med       Date:  2000-07-24

Review 6.  Hormone replacement therapy: the benefits in tailoring the regimen and dose.

Authors:  M Gambacciani; A R Genazzani
Journal:  Maturitas       Date:  2001-12-14       Impact factor: 4.342

7.  Tibial quantitative ultrasound versus whole-body and lumbar spine DXA in a Dutch pediatric and adolescent population.

Authors:  R R van Rijn; I M van der Sluis; M H Lequin; S G Robben; S M de Muinck Keizer-Schrama; W C Hop; C van Kuijk
Journal:  Invest Radiol       Date:  2000-09       Impact factor: 6.016

8.  [Bone mineral density in primary hyperparathyroidism].

Authors:  J Kosowicz; D Baszko-Błaszyk; W Horst-Sikorska; A Baumann-Antczak
Journal:  Pol Arch Med Wewn       Date:  1999-02

9.  Quantitative ultrasound assessment of bone in patients with primary hyperparathyroidism.

Authors:  S Minisola; R Rosso; A Scarda; M T Pacitti; E Romagnoli; G Mazzuoli
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

10.  Decreased cortical and increased cancellous bone in two children with primary hyperparathyroidism.

Authors:  M I Boechat; S J Westra; C Van Dop; F Kaufman; V Gilsanz; T F Roe
Journal:  Metabolism       Date:  1996-01       Impact factor: 8.694

View more
  3 in total

1.  Bone disease in primary hyperparathyrodism.

Authors:  Claudio Marcocci; Luisella Cianferotti; Filomena Cetani
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

2.  Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonography.

Authors:  J A Kanis; O Johnell; A Oden; C De Laet; F de Terlizzi
Journal:  Osteoporos Int       Date:  2004-12-07       Impact factor: 4.507

3.  Quantitative ultrasound applied to metacarpal bone in infants.

Authors:  Francesco Savino; Serena Viola; Stefania Benetti; Simone Ceratto; Valentina Tarasco; Maria Maddalena Lupica; Luca Cordero di Montezemolo
Journal:  PeerJ       Date:  2013-08-27       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.